These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21907684)

  • 21. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
    Morales A
    BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression: Pro.
    Morgentaler A
    J Urol; 2016 Oct; 196(4):985-8. PubMed ID: 27449261
    [No Abstract]   [Full Text] [Related]  

  • 23. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.
    Yassin A; Salman M; Talib RA; Yassin DJ
    Aging Male; 2017 Jun; 20(2):125-133. PubMed ID: 28282997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testosterone deficiency syndrome: treatment and cancer risk.
    Raynaud JP
    J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):96-105. PubMed ID: 19429438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
    Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
    J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Management of androgen deficiency symptoms].
    Schirren C
    Munch Med Wochenschr; 1968 Jul; ():Suppl 32:1-2. PubMed ID: 5755042
    [No Abstract]   [Full Text] [Related]  

  • 27. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer.
    Meza J; Weaver K; Martin S
    Am Fam Physician; 2013 Oct; 88(8):Online. PubMed ID: 24364582
    [No Abstract]   [Full Text] [Related]  

  • 28. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
    Halland A; Jønler M; Pedersen KV
    Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone deficiency in men with heart failure: pathophysiology and its clinical, prognostic and therapeutic implications.
    Jankowska EA; Tkaczyszyn M; Kalicińska E; Banasiak W; Ponikowski P
    Kardiol Pol; 2014; 72(5):403-9. PubMed ID: 24526551
    [No Abstract]   [Full Text] [Related]  

  • 30. Re: Abraham Morgentaler, Abdulmaged M. Traish. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310-21.
    Friedman AE
    Eur Urol; 2009 Jul; 56(1):e4; author reply e5. PubMed ID: 19349108
    [No Abstract]   [Full Text] [Related]  

  • 31. Testosterone deficiency in men: whom to evaluate, what to measure, and how to treat.
    Miranda JJ; Laufgraben MJ
    Med Health R I; 2011 Mar; 94(3):69-70, 73. PubMed ID: 21488528
    [No Abstract]   [Full Text] [Related]  

  • 32. Is testosterone a friend or a foe of the prostate?
    Jannini EA; Gravina GL; Morgentaler A; Morales A; Incrocci L; Hellstrom WJ
    J Sex Med; 2011 Apr; 8(4):946-55. PubMed ID: 21457469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testosterone deficiency in men. Diagnosis and management.
    Allan CA; McLachlan RI
    Aust Fam Physician; 2003 Jun; 32(6):422-7. PubMed ID: 12833767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: Smaller prostate size predicts high grade prostate cancer at final pathology. M. R. Newton, S. Phillips, S. S. Chang, P. E. Clark, M. S. Cookson, R. Davis, J. H. Fowke, S. D. Herrell, R. Baumgartner, R. Chan, V. Mishra, J. D. Blume, J. A. Smith, Jr. and D. A. Barocas. J Urol 2010; 184: 930-937.
    Calışkan S
    J Urol; 2011 Apr; 185(4):1537-8; author reply 1538. PubMed ID: 21349547
    [No Abstract]   [Full Text] [Related]  

  • 35. Testosterone treatment in the aging male: myth or reality?
    Nigro N; Christ-Crain M
    Swiss Med Wkly; 2012; 142():w13539. PubMed ID: 22430839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testosterone replacement therapy for late-onset hypogonadism.
    Cunningham GR
    Nat Clin Pract Urol; 2006 May; 3(5):260-7. PubMed ID: 16691239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations.
    Morgentaler A; Conners WP
    Asian J Androl; 2015; 17(2):206-11. PubMed ID: 25652633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late-onset male hypogonadism and testosterone replacement therapy in primary care.
    Brunton SA; Sadovsky R
    J Fam Pract; 2010 Jul; 59(7 Suppl):S1-8. PubMed ID: 20625573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re: Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study: L. C. Macleod, W. J. Ellis, L. F. Newcomb, Y. Zheng, J. D. Brooks, P. R. Carroll, M. E. Gleave, R. S. Lance, P. S. Nelson, I. M. Thompson, Jr., A. A. Wagner, J. T. Wei and D. W. Lin J Urol 2017;197:1026-1033.
    Denize J; Nouhaud FX; Cornu JN; Pfister C
    J Urol; 2017 Sep; 198(3):709-711. PubMed ID: 28579000
    [No Abstract]   [Full Text] [Related]  

  • 40. Testosterone Deficiency and the Prostate.
    Alukal JP; Lepor H
    Urol Clin North Am; 2016 May; 43(2):203-8. PubMed ID: 27132577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.